Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Trial to Determine the Impact of Lymphedema Therapy on Quality of Life and Disease Severity in Patients With Post-Thrombotic Syndrome
Brief Summary: The purpose of this study is to determine if complex lymphedema therapy is effective in decreasing disease severity and improving quality of life in patients with post thrombotic syndrome.


Options:
A: Inclusion Criteria:

* Age \>18 years.
* Diagnosis of post thrombotic syndrome.
* Median life expectancy of greater than 2 years.
* Previous history of lower extremity deep venous thrombosis.

Exclusion Criteria:

* Acute venous thrombosis of the lower extremity within the last 180 days.
* Unable to participate in lymphedema therapy due to monetary, physical or transportation limitations.
* Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant women and women in their first post-partum month.
B: Inclusion Criteria:

* Diagnosis of chronic kidney disease and receiving dialysis treatment
* Previous experience of at least 2 or more muscle cramps per month in at least 3 of the last 6 months
* Men or women aged 18 years and older
* Capacity to provide informed consent

Exclusion Criteria:

* Patients less than 18 years of age
* Women who are pregnant and the human fetus
* Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study and/or likely to cause death within the study duration
* Participation in another clinical during the last 12 weeks
* Known allergic reactions against any component of the study drug or its comparator(s)
* Known contraindication to any component of the study drug or its comparator(s)
* Concurrent diseases which exclude the administration of therapy as outlined by the study protocol
* Subjects who, in the opinion of the investigator, are not likely to complete the study for whatever reason.
C: Inclusion Criteria:

Signed informed consent before any procedure or assessment is done. Age over 21 years old. Over 4 episodes of documented NLC during 2 weeks of eligibility screening (for the treatment phase).

Insured by Clalit Health Services (CHS). Hebrew speaking

Exclusion Criteria:

Pregnancy Currently taking Quinidine or Magnesium additive Renal failure - serum creatinine more than 2 mg/DL or estimated glomerular filtration rate (eGFR) less than 60 ml/min (the worst, ascertained by the participant electronic records in the last 6 months). If the result is near these limits (i.e. serum creatinin 1.5-2) a second analysis will be done near the study enrollment.

Major neurological disease- ALS, MS, Paraplegia or Quadriplegia.
D: Inclusion Criteria:

* Biopsy-proven or clinically evident cirrhosis
* Able to perform exercise

Exclusion Criteria:

* Overt hepatic encephalopathy grades 3 or 4
* Cardiovascular complications (pulmonary hypertension, heart failure)
* Diabetes mellitus and microangiopathic complications, or under treatment with insulin
* Renal failure
* Portal hypertension with high risk for variceal bleeding
* Hepatocellular carcinoma

Answer: A